Axsome: Axsome, Teva settle litigation over Auvelity
Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted, or on or after Sept. 30, 2038, if no pediatric exclusivity is granted.
Read full article »
Axsome is a New York-based biopharmaceutical company that researches and develops novel therapies for the treatment of central nervous system disorders.
Read more